ScoreWhy is OSE Immunotherapeutics SA ?
1
Flat results in Jun 25
- PRE-TAX PROFIT(Q) At EUR -20.19 MM has Fallen at -134.76%
- NET PROFIT(Q) At EUR -17.12 MM has Fallen at -129.44%
- DEBTORS TURNOVER RATIO(HY) Lowest at 0.22 times
2
With ROE of -70.38%, it has a Very Attractive valuation with a 1.69 Price to Book Value
- Over the past year, while the stock has generated a return of -50.60%, its profits have fallen by -174.5%
3
Below par performance in long term as well as near term
- Along with generating -50.60% returns in the last 1 year, the stock has also underperformed France CAC 40 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to OSE Immunotherapeutics SA should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is OSE Immunotherapeutics SA for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
OSE Immunotherapeutics SA
-100.0%
-1.20
48.70%
France CAC 40
0.34%
-0.10
17.53%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-32.91%
EBIT Growth (5y)
-205.15%
EBIT to Interest (avg)
-13.03
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.27
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.46%
ROE (avg)
12.50%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.69
EV to EBIT
-1.78
EV to EBITDA
-1.92
EV to Capital Employed
1.78
EV to Sales
36.85
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-100.32%
ROE (Latest)
-70.38%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
OPERATING CASH FLOW(Y)
Highest at EUR 21.95 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
-6What is not working for the Company
PRE-TAX PROFIT(Q)
At EUR -20.19 MM has Fallen at -134.76%
NET PROFIT(Q)
At EUR -17.12 MM has Fallen at -129.44%
DEBTORS TURNOVER RATIO(HY)
Lowest at 0.22 times
OPERATING PROFIT(Q)
Lowest at EUR -21.86 MM
Here's what is working for OSE Immunotherapeutics SA
Operating Cash Flow
Highest at EUR 21.95 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (EUR MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for OSE Immunotherapeutics SA
Pre-Tax Profit
At EUR -20.19 MM has Fallen at -134.76%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (EUR MM)
Net Profit
At EUR -17.12 MM has Fallen at -129.44%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (EUR MM)
Operating Profit
Lowest at EUR -21.86 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (EUR MM)
Debtors Turnover Ratio
Lowest at 0.22 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
